Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLINI pre-operative nivolumab trial in early breast cancer
NL-OMON60757Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab and relatlimab in breast cancer (4 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathological complete response rate. Started Aug 2019; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60757.